Brief: Siemens Healthineers - For FY 2027, Expect Comparable Revenue Growth Between 4.0% And 5.0% Over FY 2026
BRIEF-Siemens Healthineers - For FY 2027, Expect Comparable Revenue Growth Between 4.0% And 5.0% Over FY 2026 Nov 5 (Reuters) - SIEMENS HEALTHINEERS AG SHLG.DE:
Q4 REVENUE UP 7.3% AT EUR 6.78 BILLION VERSUS CONSENSUS AT 6.74 BILLION
Q4 ADJUSTED EBIT MARGIN AT 15.9%
Q4 NET INCOME UP 0.3% AT EUR 599 MILLION
FOR FY 2027, EXPECT COMPARABLE REVENUE GROWTH BETWEEN 4.0% AND 5.0% OVER FY 2026
Q4 ADJUSTED EBIT DOWN 2% AT EUR 1.08 BILLION VERSUS CONSENSUS AT EUR 1.11 BILLION
FOR FY 2027 ADJUSTED BASIC EPS, WE EXPECT A RANGE OF BETWEEN €2.20 AND €2.40
CO WILL CHANGE ITS NAME TO 'HEALTHINEERS'
TO REBRAND IN VITRO DIAGNOSTICS BUSINESS AS OLYRIAN DIAGNOSTICS
INITIATED CARVE-OUT PROCESS FOR IN VITRO DIAGNOSTICS BUSINESS, IMPORTANT STEP TOWARD ESTABLISHING STANDALONE COMPANY
Further company coverage: SHLG.DE
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))
Recent news on Siemens Healthineers AG
See all newsSiemens Healthineers forecasts slower 2027 growth as China weakness persists (updated)
Siemens Healthineers seen sliding after 'not good enough' outlook
Siemens Healthineers begins carve-out of diagnostics unit amid China weakness (updated)
Brief: Siemens Healthineers - For FY 2027, Expect Comparable Revenue Growth Between 4.0% And 5.0% Over FY 2026
Siemens Healthineers starts Diagnostics carve-out, names unit Olyrian